Illumina reagents and consumables
Ended Awarded Last action
- Contract number
- 75N91026F00002
- Awardee
-
Illumina, Inc. UEI KMW3CRWNAAF3
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $213,371
Award facts
- Contract value 100% obligated
- $213,370.76 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 334516 Analytical Laboratory Instrument Manufacturing
- PSC
- 6640 Laboratory Equipment And Supplies
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92122, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a delivery order valued at $213,370.76 to Illumina, Inc. for Illumina reagents and consumables. The award, issued on February 24, 2026, with an ultimate completion date of March 6, 2026, utilizes firm fixed-price pricing and does not include a set-aside designation. Performance will be conducted at Illumina's San Diego, California facility. This delivery order represents a procurement of specialized molecular biology consumables and reagent kits that support the National Cancer Institute's genomic research and cancer diagnostics initiatives, leveraging Illumina's proprietary sequencing and genomic analysis technologies.
Illumina, Inc., a San Diego-based biotechnology company specializing in genetic sequencing platforms and genomic analysis solutions, has established itself as a primary federal contractor across multiple civilian agencies. The company maintains substantial indefinite delivery vehicle agreements, including a $45 million Indefinite Delivery/Indefinite Quantity contract with the U.S. Department of Agriculture through June 2030, and has received numerous task orders and delivery orders from the National Institutes of Health, Department of Veterans Affairs, Food and Drug Administration, and other federal agencies. Illumina's dominant market position in genetic sequencing technology positions it as a critical supplier for federally-funded research operations supporting infectious disease research, cancer diagnostics, and genomic analysis across the federal government.
Quick answers
Who was awarded contract 75N91026F00002?
75N91026F00002 was awarded to Illumina, Inc. by National Cancer Institute (National Institutes of Health) on February 24, 2026.
How much is contract 75N91026F00002 worth?
The government has obligated $213,371 on 75N91026F00002.
Is contract 75N91026F00002 an order under another contract?
Yes. 75N91026F00002 is a delivery order under 75N92020D00022, an indefinite delivery contract.
Was contract 75N91026F00002 competed?
The extent of competition for 75N91026F00002 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award